Novo Nordisk CEO, On Lilly's Diabetes Drug Approval In China, Says "It's One More Market Where There Will Be Two Critical Contenders Competing"; "Supplying All We Can", There Is No Drug Shortage Of Our Type 2 Diabetes Drug Ozempic In The U.S. Market; On Compounded Versions Of Co's Drug Semaglutide In The U.S. Says "Focused On Securing Patients Have Access To High Quality Products"
Benzinga Newsdesk - May 21, 2024, 10:53AM